PHIO vs. VTVT, ESLA, CLNN, RAPT, LTRN, CASI, TPST, CALC, ANEB, and PASG
Should you be buying Phio Pharmaceuticals stock or one of its competitors? The main competitors of Phio Pharmaceuticals include vTv Therapeutics (VTVT), Estrella Immunopharma (ESLA), Clene (CLNN), RAPT Therapeutics (RAPT), Lantern Pharma (LTRN), CASI Pharmaceuticals (CASI), Tempest Therapeutics (TPST), CalciMedica (CALC), Anebulo Pharmaceuticals (ANEB), and Passage Bio (PASG). These companies are all part of the "pharmaceutical products" industry.
Phio Pharmaceuticals vs.
vTv Therapeutics (NASDAQ:VTVT) and Phio Pharmaceuticals (NASDAQ:PHIO) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, profitability, analyst recommendations, valuation, earnings, institutional ownership and community ranking.
Phio Pharmaceuticals' return on equity of -134.57% beat vTv Therapeutics' return on equity.
In the previous week, Phio Pharmaceuticals had 3 more articles in the media than vTv Therapeutics. MarketBeat recorded 3 mentions for Phio Pharmaceuticals and 0 mentions for vTv Therapeutics. Phio Pharmaceuticals' average media sentiment score of -0.25 beat vTv Therapeutics' score of -0.55 indicating that Phio Pharmaceuticals is being referred to more favorably in the news media.
Phio Pharmaceuticals has lower revenue, but higher earnings than vTv Therapeutics. vTv Therapeutics is trading at a lower price-to-earnings ratio than Phio Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
vTv Therapeutics has a beta of 0.69, suggesting that its share price is 31% less volatile than the S&P 500. Comparatively, Phio Pharmaceuticals has a beta of 1.51, suggesting that its share price is 51% more volatile than the S&P 500.
17.5% of vTv Therapeutics shares are owned by institutional investors. Comparatively, 57.3% of Phio Pharmaceuticals shares are owned by institutional investors. 1.3% of vTv Therapeutics shares are owned by company insiders. Comparatively, 0.6% of Phio Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
vTv Therapeutics currently has a consensus price target of $35.00, indicating a potential upside of 150.54%. Phio Pharmaceuticals has a consensus price target of $36.00, indicating a potential upside of 1,351.61%. Given Phio Pharmaceuticals' higher possible upside, analysts plainly believe Phio Pharmaceuticals is more favorable than vTv Therapeutics.
vTv Therapeutics received 316 more outperform votes than Phio Pharmaceuticals when rated by MarketBeat users. However, 63.16% of users gave Phio Pharmaceuticals an outperform vote while only 57.80% of users gave vTv Therapeutics an outperform vote.
Summary
Phio Pharmaceuticals beats vTv Therapeutics on 9 of the 14 factors compared between the two stocks.
Get Phio Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for PHIO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Phio Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:PHIO) was last updated on 1/21/2025 by MarketBeat.com Staff
Free PHIO Stock Alerts